Bibliography
- Lazarou J , PomeranzBH, CoreyPN: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.JAMA279(15) , 1200–1205 (1998).
- Relling MV , PuiCH, ChengC, EvansWE: Thiopurine methyltransferase in acute lymphoblastic leukemia.Blood107(2) , 843–844 (2006).
- Guo Y , ShaferS, WellerP, UsukaJ, PeltzG: Pharmacogenomics and drug development.Pharmacogenomics6(8) , 857–864 (2005).
- van den Akker-van Marle ME , GurwitzD, DetmarSB et al.: Cost–effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe.Pharmacogenomics7(5) , 783–792 (2006).
- McCune JS , GooleyT, GibbsJP et al.: Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation.Bone Marrow Transplant.30(3) , 167–173 (2002).
- Vassal G , KoscielnyS, ChallineD et al.: Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation.Cancer Chemother. Pharmacol.37(3) , 247–253 (1996).
- Dix SP , WingardJR, MullinsRE et al.: Association of busulfan area under the curve with veno-occlusive disease following BMT.Bone Marrow Transplant.17(2) , 225–230 (1996).
- Slattery JT , SandersJE, BucknerCD et al.: Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics.Bone Marrow Transplant.16(1) , 31–42 (1995).
- Bleyzac N , SouilletG, MagronP et al.: Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.Bone Marrow Transplant.28(8) , 743–751 (2001).
- Tran HT , MaddenT, PetropoulosD et al.: Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.Bone Marrow Transplant.26(5) , 463–470 (2000).
- Bolinger AM , ZangwillAB, SlatteryJT et al.: Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation.Bone Marrow Transplant.28(11) , 1013–1018 (2001).
- Takama H , TanakaH, NakashimaD, UedaR, TakaueY: Population pharmacokinetics of intravenous busulfan in patients undergoing hematopoietic stem cell transplantation.Bone Marrow Transplant.37(4) , 345–351 (2006).
- Bartelink IH , BrediusRG, BelitserSV et al.: Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation.Biol. Blood Marrow Transplant.15(2) , 231–241 (2009).
- Bartelink IH , BrediusRG, VerversTT et al.: Once-daily intravenous busulfan with therapeutic drug monitoring compared with conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation.Biol. Blood Marrow Transplant.14(1) , 88–98 (2008).
- Bleyzac N : The use of pharmacokinetic models in paediatric onco-haematology: effects on clinical outcome through the examples of busulfan and cyclosporine.Fundam. Clin. Pharmacol.22(6) , 605–608 (2008).
- Dalle JH , WallD, TheoretY et al.: Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results.Bone Marrow Transplant.32(7) , 647–651 (2003).
- Nath CE , EarlJW, PatiN, StephenK, ShawPJ: Variability in the pharmacokinetics of intravenous busulphan given as a single daily dose to paediatric blood or marrow transplant recipients.Br. J. Clin. Pharmacol.66(1) , 50–59 (2008).
- Zwaveling J , PressRR, BrediusRG et al.: Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients.Ther. Drug Monit.30(4) , 504–510 (2008).
- Kassir TD , ChampagneMA, DuvalM, LarocqueD, LabbéL: Population pharmacokinetic of intravenous busulfan in children.Clin. Pharmacol. Ther.81(Suppl. 1) , S81 (2007).
- Czerwinski M , GibbsJP, SlatteryJT: Busulfan conjugation by glutathione S-transferases a, µ, and p.Drug Metab. Dispos.24(9) , 1015–1019 (1996).
- Ali -Osman F , AkandeO, AntounG, MaoJX, BuolamwiniJ: Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase p gene variants. Evidence for differential catalytic activity of the encoded proteins.J. Biol. Chem.272(15) , 10004–10012 (1997).
- Rebbeck TR : Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility.Cancer Epidemiol. Biomarkers Prev.6(9) , 733–743 (1997).
- Coles BF , MorelF, RauchC et al.: Effect of polymorphism in the human glutathione S-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression.Pharmacogenetics11(8) , 663–669 (2001).
- Guy CA , HoogendoornB, SmithSK, ColemanS, O‘DonovanMC, BucklandPR: Promoter polymorphisms in glutathione-S-transferase genes affect transcription.Pharmacogenetics14(1) , 45–51 (2004).
- Morel F , RauchC, ColesB, Le Ferrec E, Guillouzo A: The human glutathione transferase a locus: genomic organization of the gene cluster and functional characterization of the genetic polymorphism in the hGSTA1 promoter. Pharmacogenetics12(4) , 277–286 (2002).
- Ansari M , Lauzon-JosetJF, VachonMF et al.: Influence of GST gene polymorphisms on busulfan pharmacokinetics in children.Bone Marrow Transplant. (2009) (Epub ahead of print).
- Srivastava A , PoonkuzhaliB, ShajiRV et al.: Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation.Blood104(5) , 1574–1577 (2004).
- Bredschneider M , KleinK, MurdterTE et al.: Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: consequences for enzyme expression and busulfan conjugation.Clin. Pharmacol. Ther.71(6) , 479–487 (2002).
- Johnson L , OrchardPJ, BakerKS et al.: Glutathione S-transferase A1 genetic variants reduce busulfan clearance in children undergoing hematopoietic cell transplantation.J. Clin. Pharmacol.48(9) , 1052–1062 (2008).
- Kusama M , KubotaT, MatsukuraY et al.: Influence of glutathione S-transferase A1 polymorphism on the pharmacokinetics of busulfan.Clin. Chim. Acta368(1–2) , 93–98 (2006).
- Kim I , KeamB, LeeKH et al.: Glutathione S-transferase A1 polymorphisms and acute graft-vs-host disease in HLA-matched sibling allogeneic hematopoietic stem cell transplantation.Clin. Transplant.21(2) , 207–213 (2007).
- Krajinovic M , Lemieux-BlanchardE, ChiassonS, PrimeauM, CosteaI, MoghrabiA: Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia.Pharmacogenomics J.4(1) , 66–72 (2004).
- Rocha JC , ChengC, LiuW et al.: Pharmacogenetics of outcome in children with acute lymphoblastic leukemia.Blood105(12) , 4752–4758 (2005).